MENU

ALMS Alumis Inc. Forecast, Technical & Fundamental Analysis

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases... Show more

ALMS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
View a ticker or compare two or three
ALMS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Details
Industry
N/A
Address
280 East Grand Avenue
Phone
+1 650 231-6625
Employees
224
Web
https://www.alumis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DVYA52.55-0.02
-0.04%
iShares Asia/Pacific Dividend ETF
FMAR53.54-0.03
-0.06%
FT Vest US Equity Buffer ETF Mar
ATTR95.47-0.10
-0.11%
Arin Tactical Tail Risk ETF
ROE43.52-0.10
-0.23%
Astoria US Equal Weight Quality KingsETF
TESL13.59-0.86
-5.93%
Simplify Volt TSLA Revolution ETF

ALMS and Stocks

Correlation & Price change

A.I.dvisor tells us that ALMS and ZNTL have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALMS and ZNTL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALMS
1D Price
Change %
ALMS100%
-2.29%
ZNTL - ALMS
33%
Poorly correlated
-2.92%
MRNA - ALMS
30%
Poorly correlated
-2.23%
VKTX - ALMS
27%
Poorly correlated
+2.62%
SNDX - ALMS
27%
Poorly correlated
-0.58%
DRUG - ALMS
27%
Poorly correlated
-4.20%
More
Alumis (ALMS) stock Forecast, Price Targets and Analysts Predictions - Tickeron.com